PET PET
  • My Account
  • Subscribe
Become a Friend Donate
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • My Account
  • Subscribe
  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements
PETBioNewsNewsGene sheds light on heart drug response

BioNews

Gene sheds light on heart drug response

Published 9 June 2009 posted in News and appears in BioNews 297

Author

BioNews

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.

US researchers have identified a genetic variation that affects a person's response to beta-blockers - drugs used to treat patients with heart failure. Scientists at the University of Cincinnati in Ohio have discovered that a tiny inherited difference in the protein targeted by beta-blockers may determine whether the drug works or...

US researchers have identified a genetic variation that affects a person's response to beta-blockers - drugs used to treat patients with heart failure. Scientists at the University of Cincinnati in Ohio have discovered that a tiny inherited difference in the protein targeted by beta-blockers may determine whether the drug works or not. Stephen Liggett's team looked at two versions of the beta-1 andrenergic receptor gene, known as Arg and Gly. Mice with two Arg gene types are both more susceptible to heart failure, and more responsive to beta-blockers. To see if the same was true for people, Liggett's team recruited 1040 volunteers, all affected by severe heart failure.


The team, who reported their results at the recent meeting of the American Association for the Advancement of Science (AAAS), gave a beta-blocker called bucindolol to half the participants, and a placebo to the rest. They followed the patients' progress for up to five years, and also determined their receptor gene type. Because everyone inherits two copies of the gene, one from each parent, a person can have either two Arg gene types, two Gly genes, or one of each.


The scientists found that people with two copies of the Arg receptor type benefited most from the drug, with 82 per cent surviving, compared to 65 per cent of those taking the placebo. But patients who had either one copy of each receptor type, or two copies of the Gly version did no better than the patients with two Arg receptors given the placebo. Liggett now intends to carry out a larger study, to confirm the findings. However, all patients would be given the bucindolol this time, since it would be unethical to give people with two Arg genes the placebo, says Liggett.


Liggett predicts that by 2010, it will be possible for doctors to tailor an individual's treatment according to their genes, an approach called pharmacogenetics. Speaking at the AAAS meeting, Kathleen Giacomini from the University of California said that other teams in the US are currently looking at tailored treatments for asthma, cancer, cardiovascular disease and depression.

Leave a Reply Cancel reply

You must be logged in to post a comment.

« Second cloning licence issued in UK

Data-Label The UK's Leading Supplier Of Medical Labels & Asset Labels

RetiringDentist.co.uk The UK's Leading M&A Company.
easyfundraising
amazon

This month in BioNews

  • Popular
  • Recent
13 June 2022 • 2 minutes read

Drop in diversity of blood stem cells leads to old-age health issues

5 July 2022 • 1 minute read

No difference between fresh and frozen sperm for IUI

4 July 2022 • 2 minutes read

Shorter IVF protocol reduces risk of OHSS

4 July 2022 • 2 minutes read

USA scrambles to understand implications of Roe v Wade on fertility industry

4 July 2022 • 2 minutes read

Genetic and epigenetic causes of IVF embryo arrest discovered

4 July 2022 • 2 minutes read

Dutch donor-conceived people seek answers

Subscribe to BioNews and other PET updates for free.

Subscribe
  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856

Subscribe to BioNews and other PET updates for free.

Subscribe
PET PET

PET is an independent charity that improves choices for people affected by infertility and genetic conditions.

  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Navigation

  • About Us
  • Get Involved
  • Donate
  • BioNews
  • Events
  • Engagement
  • Jobs & Opportunities
  • Contact Us

BioNews

  • News
  • Comment
  • Reviews
  • Elsewhere
  • Topics
  • Glossary
  • Newsletters

Other

  • My Account
  • Subscribe

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856